ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,675.41
0.42%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Altimmune Inc (ALT)

  7. Altimmune Inc (ALT) Noticias

ALT Altimmune Inc

7.20
0.00 (0.00%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Altimmune Inc ALT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 7.20 23:00:03
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
7.18 6.90 7.42 7.26 7.20
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202416:24GLOBEAltimmune Statement on the Passing of Dr. Stephen Harrison
27/3/202406:00GLOBEAltimmune Announces Positive Lean Mass Preservation Data for..
27/3/202405:57IHMARKETNEWSU.S. Stock Index Futures Point to a Rebound, Oil See..
20/3/202406:30GLOBEAltimmune to Report Fourth Quarter and Full Year 2023..
14/2/202411:04EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202405:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202417:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202417:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202417:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202410:49EDGAR2Form SC 13G - Statement of acquisition of beneficial..
04/1/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202406:30GLOBEAltimmune Announces Presentation of Pemvidutide Clinical..
08/12/202307:35GLOBEWater Tower Research US Climate Virtual Investor Conference:..
04/12/202307:35GLOBEWater Tower Research US Climate Investor Conference Agenda..
30/11/202315:28EDGAR2Form 8-K - Current report
30/11/202315:24GLOBEAltimmune Announces Positive Topline Results from MOMENTUM..
07/11/202315:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:06EDGAR2Form 8-K - Current report
07/11/202306:00GLOBEAltimmune Announces Third Quarter 2023 Financial Results and..
31/10/202306:30GLOBEAltimmune to Report Third Quarter 2023 Financial Results and..
26/10/202307:15DJNAltimmune Gets FDA Fast-Track Designation for Pemvidutide in..
26/10/202306:30GLOBEAltimmune Granted Fast Track Designation by FDA for..
25/10/202306:30GLOBEAltimmune to Present New Data on the Anti-Inflammatory and..
17/10/202306:30GLOBEAltimmune to Participate at Two Upcoming Investor..
29/9/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202315:55EDGAR2Form 8-K - Current report
26/9/202306:30GLOBEAltimmune Announces Oral Presentation of Pemvidutide..
12/9/202306:30GLOBEAltimmune Announces Completion of Dosing in the Phase 2..
30/8/202306:30GLOBEAltimmune to Participate at Two Upcoming Investor..
16/8/202315:14EDGAR2Form ARS - Annual Report to Security Holders
16/8/202315:10EDGAR2Form DEF 14A - Other definitive proxy statements
15/8/202317:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202306:04EDGAR2Form 8-K - Current report
10/8/202306:00GLOBEAltimmune Announces Second Quarter 2023 Financial Results..

Su Consulta Reciente

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados